PMEL and metastatic melanoma: In another phase I trial, a combination of nivolumab with the multipeptide vaccine (gp100, MART-1, and NY-ESO-1 with Montanide ISA-51 VG) as an adjuvant in resected stages IIIC and IV patients with metastatic melanoma was conducted by the same group.